Cybin (CYBN) Growing IP Supports Faster & Shorter Psychedelic Treatments

Share:

Midas Letter Podcast

Business


Cybin Inc (NEO:CYBN, NYSEAMERICAN:CYBN) is a drug development company with four active psychedelic clinical programs targeting Major Depressive Disorder, Alcohol Use Disorder and Therapy Resistant Psychiatric Disorders (CYB001, CYB003, CYB004, CYB005). But, it’s not just four molecules the company is testing, Cybin has […]